In this studio-based webinar, a multidisciplinary expert panel will address the new treatment landscape of metastatic UCa via interactive case discussions on managing AEs and the role of molecular testing. Expert Panel Philippe Barthélémy, Medical Oncology, Strasbourg Cancer Institute, Strasbourg, France Viktor Grünwald, Medical Oncology, University Hospital Essen, Essen, Germany Sylvie Rottey, Medical Oncology, Ghent University Hospital, Ghent, Belgium Emmanuel Seront, Medical Oncology, Saint-Luc University Hospital, Brussels, Belgium Bernadett Szabados, Urology, University College London Hospital & Barts Cancer Institute, London, UK Learning objectives Translate the newest clinical trial data for metastatic UCa to clinical practice. Recognise AEs of novel therapies and use approaches for their appropriate management. Assess the relevance of molecular tumour testing to guide the management of metastatic UCa. EACCME accreditation has been applied for Organised by ISSECAM In collaborati

In this studio-based webinar, a multidisciplinary expert panel will address the new treatment landscape of metastatic UCa via interactive case discussions on managing AEs and the role of molecular testing. Expert Panel Philippe Barthélémy, Medical Oncology, Strasbourg Cancer Institute, Strasbourg, France Viktor Grünwald, Medical Oncology, University Hospital Essen, Essen, Germany Sylvie Rottey, Medical Oncology, Ghent University Hospital, Ghent, Belgium Emmanuel Seront, Medical Oncology, Saint-Luc University Hospital, Brussels, Belgium Bernadett Szabados, Urology, University College London Hospital & Barts Cancer Institute, London, UK Learning objectives Translate the newest clinical trial data for metastatic UCa to clinical practice. Recognise AEs of novel therapies and use approaches for their appropriate management. Assess the relevance of molecular tumour testing to guide the management of metastatic UCa. EACCME accreditation has been applied for Organised by ISSECAM In collaborati

In this studio-based webinar, a multidisciplinary expert panel will address the new treatment landscape of metastatic UCa via interactive case discussions on managing AEs and the role of molecular testing. Expert Panel Philippe Barthélémy, Medical Oncology, Strasbourg Cancer Institute, Strasbourg, France Viktor Grünwald, Medical Oncology, University Hospital Essen, Essen, Germany Sylvie Rottey, Medical Oncology, Ghent University Hospital, Ghent, Belgium Emmanuel Seront, Medical Oncology, Saint-Luc University Hospital, Brussels, Belgium Bernadett Szabados, Urology, University College London Hospital & Barts Cancer Institute, London, UK Learning objectives Translate the newest clinical trial data for metastatic UCa to clinical practice. Recognise AEs of novel therapies and use approaches for their appropriate management. Assess the relevance of molecular tumour testing to guide the management of metastatic UCa. EACCME accreditation has been applied for Organised by ISSECAM In collaborati

In this studio-based webinar, a multidisciplinary expert panel will address the new treatment landscape of metastatic UCa via interactive case discussions on managing AEs and the role of molecular testing. Expert Panel Philippe Barthélémy, Medical Oncology, Strasbourg Cancer Institute, Strasbourg, France Viktor Grünwald, Medical Oncology, University Hospital Essen, Essen, Germany Sylvie Rottey, Medical Oncology, Ghent University Hospital, Ghent, Belgium Emmanuel Seront, Medical Oncology, Saint-Luc University Hospital, Brussels, Belgium Bernadett Szabados, Urology, University College London Hospital & Barts Cancer Institute, London, UK Learning objectives Translate the newest clinical trial data for metastatic UCa to clinical practice. Recognise AEs of novel therapies and use approaches for their appropriate management. Assess the relevance of molecular tumour testing to guide the management of metastatic UCa. EACCME accreditation has been applied for Organised by ISSECAM In collaborati

In this studio-based webinar, a multidisciplinary expert panel will address the new treatment landscape of metastatic UCa via interactive case discussions on managing AEs and the role of molecular testing. Expert Panel Philippe Barthélémy, Medical Oncology, Strasbourg Cancer Institute, Strasbourg, France Viktor Grünwald, Medical Oncology, University Hospital Essen, Essen, Germany Sylvie Rottey, Medical Oncology, Ghent University Hospital, Ghent, Belgium Emmanuel Seront, Medical Oncology, Saint-Luc University Hospital, Brussels, Belgium Bernadett Szabados, Urology, University College London Hospital & Barts Cancer Institute, London, UK Learning objectives Translate the newest clinical trial data for metastatic UCa to clinical practice. Recognise AEs of novel therapies and use approaches for their appropriate management. Assess the relevance of molecular tumour testing to guide the management of metastatic UCa. EACCME accreditation has been applied for Organised by ISSECAM In collaborati

In this studio-based webinar, a multidisciplinary expert panel will address risk-adapted treatment selection after nephrectomy via interactive case discussions on adjuvant therapy in RCC. Expert Panel Philippe Barthélémy, Medical Oncology, Strasbourg Cancer Institute, Strasbourg, France Viktor Grünwald, Medical Oncology, University Hospital Essen, Essen, Germany Sylvie Rottey, Medical Oncology, Ghent University Hospital, Ghent, Belgium Bernadett Szabados, Urology, University College London Hospital & Barts Cancer Institute, London, UK Learning objectives Understand the newest data on adjuvant therapy in RCC Identify which RCC patients are at high risk of recurrence post-nephrectomy and may benefit from adjuvant therapy Choose the most appropriate adjuvant therapy for localised RCC at a patient-specific level EACCME accreditation has been applied for Organised by ISSECAM In collaboration with OncoAlert Supported by an independent educational grant from MSD

In this studio-based webinar, a multidisciplinary expert panel will address the new treatment landscape of metastatic UCa via interactive case discussions on managing AEs and the role of molecular testing. Expert Panel Philippe Barthélémy, Medical Oncology, Strasbourg Cancer Institute, Strasbourg, France Viktor Grünwald, Medical Oncology, University Hospital Essen, Essen, Germany Sylvie Rottey, Medical Oncology, Ghent University Hospital, Ghent, Belgium Emmanuel Seront, Medical Oncology, Saint-Luc University Hospital, Brussels, Belgium Bernadett Szabados, Urology, University College London Hospital & Barts Cancer Institute, London, UK Learning objectives Translate the newest clinical trial data for metastatic UCa to clinical practice. Recognise AEs of novel therapies and use approaches for their appropriate management. Assess the relevance of molecular tumour testing to guide the management of metastatic UCa. EACCME accreditation has been applied for Organised by ISSECAM In collaborati